drugset
Drugs / Fadanafil
last change Jun 2024 re-read 3 minutes ago

Fadanafil

also known as XZP-5849
Investigated by
Sihuan Pharmaceutical Holdings Group Ltd.

Trials 2

today NCT04467203 · Ph 1 NCT04312568 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04467203 Apr → May 2019 — Sihuan Pharmaceutical Holdings Group Ltd. Completed No outcome recorded
Phase 1 NCT04312568 Aug → Dec 2018 — Sihuan Pharmaceutical Holdings Group Ltd. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2024-06-13 Joincare Pharmaceutical Group Industry Co., Ltd 丽珠医药就复达那非（XZP-5849）产品与轩竹生物达成独家开发及商业化授权许可合作 joincare.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Fadanafil ClinicalTrials.gov intervention name — accepted as the source's own label NCT04312568 ↗
1

NCT04467203 ↗
Known as XZP-5849 “The purpose of this study is to evaluate the safety , tolerability, and pharmacokinetics of ascending single dose Fadanafil （XZP-5849） in Chinese healthy adult male subjects.” NCT04312568 ↗
Action Inhibit “selective phosphodiesterase (PDE5) inhibitor” NCT04467203 ↗
Route Oral “administered orally” NCT04467203 ↗